David A. Siegel Theravance Biopharma, Inc. Transaction History

Two Sigma Advisers, LP

$43.8 Billion
Q2 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 33,900 shares of TBPH stock, worth $296,625. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,900

Holding current value

$296,625

% of portfolio

0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$8.29 - $9.92 $281,031 - $336,288	33,900 New	33,900 $287,000
Q2 2023 Aug 14, 2023	SELL	$10.16 - $11.92 $3.96 Million - $4.64 Million	-389,500 Reduced 80.51%	94,300 $976,000
Q1 2023 May 15, 2023	SELL	$9.87 - $11.44 $5.18 Million - $6 Million	-524,800 Reduced 52.03%	483,800 $5.25 Million
Q4 2022 Feb 14, 2023	BUY	$9.65 - $11.34 $3.01 Million - $3.54 Million	312,000 Added 44.79%	1,008,600 $11.3 Million
Q3 2022 Nov 14, 2022	BUY	$8.39 - $10.22 $5.84 Million - $7.12 Million	696,600 New	696,600 $7.06 Million
Q2 2022 Aug 15, 2022	SELL	$8.41 - $10.34 $89,987 - $110,638	-10,700 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$8.33 - $12.96 $89,131 - $138,672	10,700 New	10,700 $102,000
Q2 2021 Aug 16, 2021	SELL	$14.52 - $22.46 $432,696 - $669,308	-29,800 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$16.57 - $21.08 $119,304 - $151,776	-7,200 Reduced 19.46%	29,800 $608,000
Q4 2020 Feb 16, 2021	SELL	$14.89 - $20.16 $637,292 - $862,848	-42,800 Reduced 53.63%	37,000 $657,000
Q3 2020 Nov 16, 2020	BUY	$14.79 - $22.49 $420,036 - $638,716	28,400 Added 55.25%	79,800 $1.18 Million
Q2 2020 Aug 14, 2020	BUY	$20.64 - $30.69 $1.06 Million - $1.58 Million	51,400 New	51,400 $1.08 Million

Others Institutions Holding TBPH

# of Institutions

133

Shares Held

48.7M

Call Options Held

13.9K

Put Options Held

3.1K

View Full List

About Theravance Biopharma, Inc.

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $584M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

More about TBPH

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account